Novel targets for immunotherapy in glomerulonephritis.


Journal Article

Glomerulonephritis is a common cause of chronic kidney disease and end stage renal failure. Current therapy relies on variably effective, nonspecific and toxic immunosuppression. Recent insights into underlying biology and disease pathogenesis in human glomerulonephritis combined with advances in the fields of inflammation and autoimmunity promise a cadre of novel targeted interventions. This review highlights the therapeutic potential of two antigens, alpha3 (IV)NC1 collagen and podocyte neutral endopeptidase, and two cell signaling and effector molecules, IgG Fc receptors and complement, judged to be particularly amenable to therapeutic manipulation in man. It is anticipated that continued dissection of pathogenesis in the diverse disorders that comprise the glomerulonephritides will provide the basis for individualized disease-specific therapy.

Full Text

Duke Authors

Cited Authors

  • Foster, MH

Published Date

  • September 2008

Published In

Volume / Issue

  • 2 / 3

Start / End Page

  • 531 - 545

PubMed ID

  • 19707383

Pubmed Central ID

  • 19707383

International Standard Serial Number (ISSN)

  • 1177-5475

Digital Object Identifier (DOI)

  • 10.2147/btt.s2764


  • eng

Conference Location

  • New Zealand